132 related articles for article (PubMed ID: 1976017)
1. (R)- and (S)-5-hydroxy-2-(dipropylamino)tetralin (5-OH DPAT): assessment of optical purities and dopaminergic activities.
Karlsson A; Björk L; Pettersson C; Andén NE; Hacksell U
Chirality; 1990; 2(2):90-5. PubMed ID: 1976017
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology of the novel 5-hydroxytryptamine1A receptor antagonist (S)-5-fluoro-8-hydroxy-2-(dipropylamino)tetralin: inhibition of (R)-8-hydroxy-2-(dipropylamino)tetralin-induced effects.
Björk L; Cornfield LJ; Nelson DL; Hillver SE; Andén NE; Lewander T; Hacksell U
J Pharmacol Exp Ther; 1991 Jul; 258(1):58-65. PubMed ID: 1830099
[TBL] [Abstract][Full Text] [Related]
3. Differential serotoninergic and dopaminergic activities of the (R)- and the (S)-enantiomers of 2-(di-n-propylamino)tetralin.
Yu H; Liu Y; Malmberg A; Mohell N; Hacksell U; Lewander T
Eur J Pharmacol; 1996 May; 303(3):151-62. PubMed ID: 8813561
[TBL] [Abstract][Full Text] [Related]
4. Further characterization of structural requirements for agonists at the striatal dopamine D2 receptor and a comparison with those at the striatal dopamine D1 receptor. Studies with a series of monohydroxyaminotetralins on acetylcholine release from rat striatum.
Seiler MP; Markstein R
Mol Pharmacol; 1984 Nov; 26(3):452-7. PubMed ID: 6238231
[TBL] [Abstract][Full Text] [Related]
5. A C2-methylated derivative of the 5-hydroxy-tryptamine-receptor agonist 8-hydroxy-2-(dipropylamino)tetralin (8-OH DPAT).
Mellin C; Liu Y; Hacksell U; Björk L; Andén NE
Acta Pharm Suec; 1987; 24(4):153-60. PubMed ID: 2964167
[No Abstract] [Full Text] [Related]
6. 5-HT1A and alpha-2 adrenergic receptors mediate the hyperglycemic and hypoinsulinemic effects of 8-hydroxy-2-(di-n-propylamino)tetralin in the conscious rat.
Chaouloff F; Jeanrenaud B
J Pharmacol Exp Ther; 1987 Dec; 243(3):1159-66. PubMed ID: 2826757
[TBL] [Abstract][Full Text] [Related]
7. Influence of route of administration on potency of the selective 5HT-1A agonist, 8-hydroxy-2-(di-n-propylamino)tetralin, in rats.
Fuller RW; Snoddy HD
Res Commun Chem Pathol Pharmacol; 1987 Dec; 58(3):409-12. PubMed ID: 2449711
[TBL] [Abstract][Full Text] [Related]
8. (S)-5-fluoro-8-hydroxy-2-(dipropylamino)tetralin: a putative 5-HT1A-receptor antagonist.
Hillver SE; Björk L; Li YL; Svensson B; Ross S; Andén NE; Hacksell U
J Med Chem; 1990 Jun; 33(6):1541-4. PubMed ID: 2140413
[No Abstract] [Full Text] [Related]
9. [Multiple [3H]8-hydroxy-2-(di-n-propylamino)-tetralin binding sites in rat brain: modulation by GTP and cations].
Yokota N; Yamawaki S; Hayakawa H; Yoshida R; Sarai K
Yakubutsu Seishin Kodo; 1989 Jun; 9(2):197-206. PubMed ID: 2530729
[TBL] [Abstract][Full Text] [Related]
10. Resolved N,N-dialkylated 2-amino-8-hydroxytetralins: stereoselective interactions with 5-HT1A receptors in the brain.
Björk L; Höök BB; Nelson DL; Andén NE; Hacksell U
J Med Chem; 1989 Apr; 32(4):779-83. PubMed ID: 2522991
[TBL] [Abstract][Full Text] [Related]
11. (R)- and (S)-8-acetyl-2-(dipropylamino)tetralin (LY-41): two novel 5-HT1A receptor agonists.
Yu H; Liu Y; Hacksell U; Lewander T
Eur J Pharmacol; 1993 Jan; 231(1):69-76. PubMed ID: 8444282
[TBL] [Abstract][Full Text] [Related]
12. Evidence for selective inhibition of limbic forebrain dopamine synthesis by 8-OH-DPAT in the rat.
Ahlenius S; Hillegaart V; Wijkström A
Naunyn Schmiedebergs Arch Pharmacol; 1989 May; 339(5):551-6. PubMed ID: 2570361
[TBL] [Abstract][Full Text] [Related]
13. Novel dopamine receptor agonists and antagonists with preferential action on autoreceptors.
Johansson AM; Arvidsson LE; Hacksell U; Nilsson JL; Svensson K; Hjorth S; Clark D; Carlsson A; Sanchez D; Andersson B
J Med Chem; 1985 Aug; 28(8):1049-53. PubMed ID: 3927002
[TBL] [Abstract][Full Text] [Related]
14. Central dopaminergic and 5-hydroxytryptaminergic effects of C3-methylated derivatives of 8-hydroxy-2-(di-n-propylamino)tetralin.
Mellin C; Björk L; Karlén A; Johansson AM; Sundell S; Kenne L; Nelson DL; Andén NE; Hacksell U
J Med Chem; 1988 Jun; 31(6):1130-40. PubMed ID: 2967376
[TBL] [Abstract][Full Text] [Related]
15. Enantiomers of monohydroxy-2-aminotetralin derivatives and their activity at dopamine autoreceptors as studied by brain dialysis.
Timmerman W; Tepper PG; Dijkstra D; Stoelwinder H; Grol CJ; Westerink BH; Horn AS
Eur J Pharmacol; 1991 Jun; 199(2):145-51. PubMed ID: 1683287
[TBL] [Abstract][Full Text] [Related]
16. Effects of the C3-methylated derivatives of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) on central 5-hydroxytryptamine receptors.
Björk L; Mellin C; Hacksell U; Andén NE
Eur J Pharmacol; 1987 Nov; 143(1):55-63. PubMed ID: 2961582
[TBL] [Abstract][Full Text] [Related]
17. Increased dopamine turnover in the ventral striatum by 8-OH-DPAT administration in the rat.
Ahlenius S; Hillegaart V; Wijkström A
J Pharm Pharmacol; 1990 Apr; 42(4):285-8. PubMed ID: 1974300
[TBL] [Abstract][Full Text] [Related]
18. Effect of 8-hydroxy-2-(di-n-propylamino) tetralin on rat prolactin secretion.
Simonovic M; Gudelsky GA; Meltzer HY
J Neural Transm; 1984; 59(2):143-9. PubMed ID: 6233394
[TBL] [Abstract][Full Text] [Related]
19. Effects of (R)-8-OH-DPAT and the enantiomers of UH-301 on motor activities in the rat: antagonism of (R)-8-OH-DPAT-induced effects.
Björk L; Fredriksson A; Hacksell U; Lewander T
Eur Neuropsychopharmacol; 1992 Jun; 2(2):141-7. PubMed ID: 1385999
[TBL] [Abstract][Full Text] [Related]
20. Determination of brain concentrations of 8-hydroxy-2-(di-n-propylamino)tetralin by liquid chromatography with electrochemical detection.
Perry KW; Fuller RW
Biochem Pharmacol; 1989 Oct; 38(19):3169-73. PubMed ID: 2530985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
